Chris Blanchette
Vice President - Clinical Data Science, Evidence Short-Term Assignment, Global Medical Affairs, Product & Portfolio Strategy Novo Nordisk
With over 20 years of experience in the healthcare and pharmaceutical industry, Dr. Blanchette is driven to help patients get the best medicines to enhance their lives. His work has focused on ensuring the right evidence is developed to determine the value of treatments to patients and the healthcare system. At Novo Nordisk, he leads a division of more than 70 employees supporting healthcare decision-making and improving patient outcomes. He focuses on developing high-performing teams and developing innovative frameworks for evidence generation and synthesis. By steering collaborative efforts and aligning global operations, his team contributes to advancing Novo Nordisk’s mission of improving care through actionable insights and impactful data
Seminars
- How is real‑world evidence being used across the full development and post‑launch lifecycle, and how should organizations integrate RWE earlier while leveraging AI and other methods to enhance decision‑making at each stage?
- How is real‑world evidence being used in practice to inform R&D and lifecycle decisions beyond methodological decisions?
- What does real‑world AI adoption look like beyond pilots, and what has been required to move from experimentation to scalable, trusted impact?
- Where are the real credibility risks when integrating AI and RWE into regulated evidence generation, and how are leading organizations managing them?
- How should companies balance speed, innovation, and scientific defensibility as AI becomes embedded across evidence generation workflows?
- What strategic and governance capabilities will distinguish evidence leaders over the next 3–5 years?
- Building integrated evidence planning frameworks that align RWE, HEOR, and clinical data across global teams and pipeline assets
- Connecting evidence generation, synthesis, and decisionmaking across functions to move beyond fragmented studies toward coordinated enterprise insight
- Embedding evidence into organizational workflows to support both internal development decisions and external stakeholder value demonstration
